ViroStatics is a privately held small pharmaceutical company dedicated to the discovery and the development of novel compounds for a multifaceted treatment of cancers and viral diseases, focusing on novel, selective, host cell kinase targeted inhibitors.

The Team and Advisors combines scientific, business, legal, and technology expertise, spanning the entire process of drug development from translational science through preclinical and clinical drug development.

ViroStatics intends to license its compounds at the preclinical stage, with a patent protection extended until 2039.


The Coronavirus pandemic (COVID-19)

ViroStatics is equipped to test any antiviral compound (under development, repurposed, small molecule, biologic, etc…) against SARS-CoV-2.

COVID-19 is in everyone’s mind and heart. We assure you that we are putting all our forces into action to fight it. Help us identifying with our research as many drugs as possible to be made immediately available to our doctors. Help our search.

October 30, 2020

ViroStatics has been selected by Meet in Italy for Life Sciences as one of the finalists pitch presentations to be held on October 30th, in virtual mode.…… Read more

July 4, 2020

ViroStatics is now fully equipped to test any compound (small molecule and/or biologic) against SARS-CoV-2…… Read more

March 19, 2020

ViroStatics is engaged to fight against COVID-19…… Read more

Developing Novel Compounds Targeting Cancers and Viruses

The Company has developed a robust pipeline of proprietary compounds to distinguish themselves from the competition through their unique kinase selectivity, efficacy and safety profiles.

Consistent with its well defined mechanism of action, ViroStatics’ lead compound has a good toxicity profile while exerting potent activity in preclinical models against most aggressive cancers with high unmet need such as pancreatic cancer, highly malignant lymphoma and acute leukemia, lung cancer and breast cancer.

LEARN MORE

ViroStatics awarded with H2020 Seal of Excellence

8 May 2019

“TOSCA” project proposal, aiming at reaching clinical readiness for VS2-370, a novel oral CDK4/6/9 inhibitor developed for the treatment of aggressive tumors (breast, lung, pancreas, haemato-oncology), for out-licensing or M&A with a Pharmaceutical Company, has been judged as a high quality proposal following highly competitive evaluation process by an international panel of independent experts and has been therefore awarded with the SEAL OF EXCELLENCE within the Horizon 2020’s SME instrument Phase 2 call H2020-EIC-SMEInst-2018-2020. Horizon 2020 is the biggest EU Research and Innovation programme ever for breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.